Your browser doesn't support javascript.
loading
Simultaneous kidney-pancreas transplantation without antilymphocyte induction.
Reddy, K S; Stratta, R J; Shokouh-Amiri, H; Alloway, R; Somerville, T; Egidi, M F; Gaber, L W; Gaber, A O.
Afiliação
  • Reddy KS; Department of Surgery, University of Kentucky Chandler Medical Center, Lexington 40536, USA.
Transplantation ; 69(1): 49-54, 2000 Jan 15.
Article em En | MEDLINE | ID: mdl-10653379
ABSTRACT

BACKGROUND:

The introduction of potent new immunosuppressive agents may allow simultaneous kidney-pancreas transplantation to be performed without antilymphocyte induction.

METHODS:

We analyzed 30 simultaneous kidney-pancreas transplantations receiving tacrolimus, mycophenolate mofetil, and steroids without without antilymphocyte induction. Eighteen patients underwent pancreas transplantation with portal-enteric (P-E) drainage and the remaining 12 had systemic bladder (S-B) drainage. Target 12 hr trough tacrolimus levels for the first 3 months after simultaneous kidney-pancreas transplantation were 15-20 ng/ml. The oral mycophenolate mofetil dose was 2-3 g/day begun immediately posttransplant in two to four divided doses. Steroids were tapered according to protocol.

RESULTS:

All patients experienced immediate function of both kidney and pancreas grafts. One-year actuarial patient, kidney, and pancreas graft survival rates are 93, 93, and 90%, respectively. Nine patients (30%) had a total of 13 rejection episodes (12 biopsy proven) including 4 within 2 weeks, 6 between 2 weeks and 3 months, and 3 beyond 3 months after simultaneous kidney-pancreas transplantation. Three rejection episodes were treated with steroids alone and 10 were treated with antilymphocyte therapy (5 OKT3 and 5 ATGAM). A total of seven patients (23%) received antilymphocyte therapy. Three patients (10%) had more than one rejection episode. Two pancreas grafts (7%) and one kidney graft (3%) were lost from rejection. Four patients (13%) developed cytomegalovirus infection, but none had tissue-invasive cytomegalovirus. At present, 22 surviving patients (81%) remain on triple immunosuppression with tacrolimus, mycophenolate mofetil, and prednisone with excellent dual graft function.

CONCLUSION:

Tacrolimus, mycophenolate mofetil, and prednisone immunosuppression without without antilymphocyte induction is safe and effective after simultaneous kidney-pancreas transplantation.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Transplante de Rim / Transplante de Pâncreas Tipo de estudo: Etiology_studies / Guideline / Incidence_studies / Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2000 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Transplante de Rim / Transplante de Pâncreas Tipo de estudo: Etiology_studies / Guideline / Incidence_studies / Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2000 Tipo de documento: Article